News

AstraZeneca, Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...
PMLive17h
AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer
AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...